Key Points
- DexCom EVP Sadie Stern sold 2,565 shares at an average price of $78.62, generating approximately $201,660. The transaction, conducted under a Rule 10b5-1 plan, reduced her holdings by 2.08% to 120,913 shares.
- DexCom reported quarterly revenue of $1.31 billion and earnings of $0.70 per share, exceeding analyst estimates, while revenue increased 13.1% year over year.
- Analysts maintain a consensus “Buy” rating with an average price target of $92.43, and institutional investors own approximately 97.75% of the company’s stock.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 2,565 shares of the business's stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total value of $201,660.30. Following the sale, the executive vice president owned 120,913 shares in the company, valued at approximately $9,506,180.06. The trade was a 2.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sadie Stern also recently made the following trade(s):
- On Monday, September 28th, Sadie Stern sold 2,565 shares of DexCom stock. The stock was sold at an average price of $86.15, for a total transaction of $220,974.75.
- On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The stock was sold at an average price of $88.37, for a total value of $226,669.05.
DexCom Stock Performance
Shares of NASDAQ DXCM opened at $78.62 on Thursday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The company has a market capitalization of $29.67 billion, a PE ratio of 31.08, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. The company's fifty day moving average price is $86.18 and its 200 day moving average price is $74.54.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the previous year, the firm earned $0.48 EPS. The firm's revenue was up 13.1% compared to the same quarter last year. On average, research analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.
Hedge Funds Weigh In On DexCom
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company's stock worth $758,487,000 after acquiring an additional 1,515,702 shares during the period. Legal & General Group Plc purchased a new stake in shares of DexCom in the second quarter valued at about $173,237,000. Janus Henderson Group PLC grew its holdings in shares of DexCom by 32.3% in the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company's stock valued at $166,077,000 after purchasing an additional 645,534 shares during the period. Deutsche Bank AG purchased a new stake in shares of DexCom in the second quarter valued at about $164,035,000. Finally, Arrowstreet Capital Limited Partnership increased its position in DexCom by 100.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company's stock worth $159,832,000 after purchasing an additional 1,275,142 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.
Analysts Set New Price Targets
Several research firms recently commented on DXCM. Raymond James Financial reissued a "strong-buy" rating and issued a $94.00 price objective on shares of DexCom in a research note on Friday, July 31st. Truist Financial set a $102.00 target price on shares of DexCom and gave the stock a "buy" rating in a research note on Friday, September 18th. Piper Sandler reaffirmed an "overweight" rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Benchmark increased their target price on shares of DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $105.00 price objective (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $92.43.
Check Out Our Latest Stock Report on DexCom
DexCom Company Profile
(
Get Free Report)
DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.
The company's product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
